BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 28593575)

  • 1. The role of hERG1 ion channels in epithelial-mesenchymal transition and the capacity of riluzole to reduce cisplatin resistance in colorectal cancer cells.
    Fortunato A
    Cell Oncol (Dordr); 2017 Aug; 40(4):367-378. PubMed ID: 28593575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combined activation of K
    Pillozzi S; D'Amico M; Bartoli G; Gasparoli L; Petroni G; Crociani O; Marzo T; Guerriero A; Messori L; Severi M; Udisti R; Wulff H; Chandy KG; Becchetti A; Arcangeli A
    Br J Cancer; 2018 Jan; 118(2):200-212. PubMed ID: 29161243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
    Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
    Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of aquaporin 5-mediated epithelial-mesenchymal transition and anti-metastatic effect by natural product Cairicoside E in colorectal cancer.
    Chen C; Ma T; Zhang C; Zhang H; Bai L; Kong L; Luo J
    Mol Carcinog; 2017 Dec; 56(12):2692-2705. PubMed ID: 28833571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
    Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF
    Oncotarget; 2016 Sep; 7(39):64136-64147. PubMed ID: 27580057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HERG1 promotes esophageal squamous cell carcinoma growth and metastasis through TXNDC5 by activating the PI3K/AKT pathway.
    Wang H; Yang X; Guo Y; Shui L; Li S; Bai Y; Liu Y; Zeng M; Xia J
    J Exp Clin Cancer Res; 2019 Jul; 38(1):324. PubMed ID: 31331361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of DAB2IP promotes cancer stem cell like signatures and indicates poor survival outcome in colorectal cancer.
    Min J; Liu L; Li X; Jiang J; Wang J; Zhang B; Cao D; Yu D; Tao D; Hu J; Gong J; Xie D
    Sci Rep; 2015 Nov; 5():16578. PubMed ID: 26564738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer.
    Toden S; Okugawa Y; Jascur T; Wodarz D; Komarova NL; Buhrmann C; Shakibaei M; Boland CR; Goel A
    Carcinogenesis; 2015 Mar; 36(3):355-67. PubMed ID: 25653233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear factor I/B promotes colorectal cancer cell proliferation, epithelial-mesenchymal transition and 5-fluorouracil resistance.
    Liu Z; Chen J; Yuan W; Ruan H; Shu Y; Ji J; Wu L; Tang Q; Zhou Z; Zhang X; Cheng Y; He S; Shu X
    Cancer Sci; 2019 Jan; 110(1):86-98. PubMed ID: 30320939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic and epigenetic down-regulation of microRNA-212 promotes colorectal tumor metastasis via dysregulation of MnSOD.
    Meng X; Wu J; Pan C; Wang H; Ying X; Zhou Y; Yu H; Zuo Y; Pan Z; Liu RY; Huang W
    Gastroenterology; 2013 Aug; 145(2):426-36.e1-6. PubMed ID: 23583431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDGF-D promotes cell growth, aggressiveness, angiogenesis and EMT transformation of colorectal cancer by activation of Notch1/Twist1 pathway.
    Chen J; Yuan W; Wu L; Tang Q; Xia Q; Ji J; Liu Z; Ma Z; Zhou Z; Cheng Y; Shu X
    Oncotarget; 2017 Feb; 8(6):9961-9973. PubMed ID: 28035069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic oxymatrine treatment induces resistance and epithelial‑mesenchymal transition through targeting the long non-coding RNA MALAT1 in colorectal cancer cells.
    Xiong Y; Wang J; Zhu H; Liu L; Jiang Y
    Oncol Rep; 2018 Mar; 39(3):967-976. PubMed ID: 29328404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers.
    Pillozzi S; Masselli M; De Lorenzo E; Accordi B; Cilia E; Crociani O; Amedei A; Veltroni M; D'Amico M; Basso G; Becchetti A; Campana D; Arcangeli A
    Blood; 2011 Jan; 117(3):902-14. PubMed ID: 21048156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. hERG1 channels modulate integrin signaling to trigger angiogenesis and tumor progression in colorectal cancer.
    Crociani O; Zanieri F; Pillozzi S; Lastraioli E; Stefanini M; Fiore A; Fortunato A; D'Amico M; Masselli M; De Lorenzo E; Gasparoli L; Chiu M; Bussolati O; Becchetti A; Arcangeli A
    Sci Rep; 2013 Nov; 3():3308. PubMed ID: 24270902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
    Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salinomycin reduces epithelial-mesenchymal transition-mediated multidrug resistance by modifying long noncoding RNA HOTTIP expression in gastric cancer cells.
    Mao Z; Wu Y; Zhou J; Xing C
    Anticancer Drugs; 2019 Oct; 30(9):892-899. PubMed ID: 30882398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing GOLPH3 gene expression reverses resistance to cisplatin in HT29 colon cancer cells via multiple signaling pathways.
    Zhou ZP; Wang LP; Hong ZS; Qiu CZ; Wang MZ; Chen ZX; Tang LF; Yu WS; Wang CX
    Int J Oncol; 2018 Sep; 53(3):1183-1192. PubMed ID: 30015866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-139-5p affects cisplatin sensitivity in human nasopharyngeal carcinoma cells by regulating the epithelial-to-mesenchymal transition.
    Shao Q; Zhang P; Ma Y; Lu Z; Meng J; Li H; Wang X; Chen D; Zhang M; Han Y; Liu H; Ma S
    Gene; 2018 Apr; 652():48-58. PubMed ID: 29427737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-223 promotes the doxorubicin resistance of colorectal cancer cells via regulating epithelial-mesenchymal transition by targeting FBXW7.
    Ding J; Zhao Z; Song J; Luo B; Huang L
    Acta Biochim Biophys Sin (Shanghai); 2018 Jun; 50(6):597-604. PubMed ID: 29701752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luteolin inhibits colorectal cancer cell epithelial-to-mesenchymal transition by suppressing CREB1 expression revealed by comparative proteomics study.
    Liu Y; Lang T; Jin B; Chen F; Zhang Y; Beuerman RW; Zhou L; Zhang Z
    J Proteomics; 2017 May; 161():1-10. PubMed ID: 28391045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.